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ABSTRACT 
Objective: To develop a simple and sensitive, high-performance thin layer chromatographic (HPTLC) method for the quantitative estimation of 
apixaban in bulk and tablets. 
Methods: Sample of apixaban was applied on silica gel 60 F254 TLC plates under pure nitrogen stream by linomat TLC applicator. Separation was 
carried out by using toluene, methanol and diethylamine as a mobile phase in a ratio of 16:3:1 v/v/v. Developed TLC plates were scanned by camag 
TLC scanner and detection was carried out at 288 nm.  
Results: Rf value of apixaban was found to be 0.4. The linearity was found from 50 to 350 ng/spot. The mean percentage recovery was found to be 
85.66with % RSD of 0.79. 
Conclusion: The present study represents first HPTLC method that deals with the estimation of apixaban. Validation results indicated that the 
developed method is simple, rapid, accurate, specific, sensitive and precise. The developed method was validated as per ICH Q2 (R1) guideline by 
studying various validation parameters like accuracy, precision, specificity, assay, LOD and LOQ. It can be concluded that the method can be used in 
routine analysis of apixaban in tablet dosage form. 
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Apixaban is chemically 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo 
piperidin-1-yl) phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo [3,4-
c]pyridine-3-carboxamide [fig. 1]. It is a new generation of oral 
anticoagulant drug that selectively inhibits coagulation factor Xa. [1]. 
It is used in thromboprophylaxis in patients following total knee 
replacement surgery with a desired efficacy and safety profile [2]. 
FDA approved apixaban (eliquis, bristol-myers squibb/pfizer) on 
december 28, 2012 for the prevention of stroke and systemic 
embolism in patients with nonvalvular atrial fibrillation (AF) [3]. 
Apixaban is not an official drug in any Pharmacopoeia. Literature 
survey reveals that some methods have been reported for their 
determination of apixaban by HPLC [4-6] and hyphenated 
techniques such as UPLC–MS/MS [7-8], LCMS [9-10], GCMS [11], 
either alone or in combination. Most of the reported methods are 
based on hyphenated techniques and overall cost of the analysis 
using these techniques is more as compared to high-performance 
thin layer chromatography [12-15]. There is no HPTLC method 
available yet for estimation of apixaban in tablets. This paper 
presents development and validation of a simple, accurate and 




Fig. 1: Chemical structure of apixaban 
 
MATERIALS AND METHODS 
Materials 
Apixaban standard was procured from Wockhardt research centre, 
Chikalthana, India as a gift sample. Commercially available tablets 
(eliquis® 5 mg of apixaban) were procured from local the market. Pre-
coated silica gel 60 f254 TLC (e-merck, Germany) plates (10x10 cm) 
were used as stationary phase and a mixture of toluene, methanol and 
diethylamine was used as mobile phase. HPLC grades of all solvents 
used for this study were obtained from merck pvt. ltd, Mumbai. 
Instrument  
The method was performed on camag (Switzerland) twin trough 
chamber, visualizer with automatic injection facility ATS 4 and TLC 
scanner 4. 
Preparation of working solution 
An accurately weighed 5 mg of apixaban was transferred into a 20 
ml test-tube. Five ml of a mixture of dimethyl formamide: methanol 
(1:4) was added to it and solution was sonicated for 15 min. This 
solution (1 mg/ml) was further diluted by dimethyl formamide: 
methanol (1:4) to obtain 100 μg/ml. 
Selection of detection wavelength 
5 μl of apixaban (1000 μg/ml) was applied using automatic injection 
facility ATS 4 on precoated silica gel 60 f254 TLC plates and scanned 
by camag TLC scanner 4.  
Analytical method validation 
The developed chromatographic method was validated for system 
suitability, linearity, range, specificity, accuracy, precision, assay, 
LOD-LOQ and robustness parameters, as per ICH guidelines [16]. 
Linearity and range 
Working standard solutions were injected under the optimized 
chromatographic conditions and peak areas were calculated at 288 nm. 
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The calibration curve was plotted between areas against corresponding 
concentrations of the drug. Linear regression data for calibration curve 
was shown in fig. 4. The range of solution has been decided according to 
a correlation coefficient of the regression equation. 
Precision 
Repeatability and intermediate precision studies were carried out 
with 10 replicates of standard solutions of apixaban (200 ng/spot). 
Area of each spot was measured at 288 nm and relative standard 
deviation (%RSD) was calculated. Inter-day precision studies were 
performed using same concentrations on three different days. The 
results of the precision study have been tabulated in (table 3). 
Accuracy  
The accuracy of the method was carried out by adding the known 
amount of drug corresponding to three given concentration levels 
(80%, 100%, 120%). 
Percent recovery of apixaban was determined at three different level 
80%, 100%, and 120% of the target concentration in triplicate. The 
results of accuracy study are shown in table 4. 
Limit of detection (LOD) and limit of quantitation (LOQ) 
Five sets of 50-350 ng/spot were prepared and the corresponding 
areas of these sets were measured. Calibration curves were plotted 
for each set. The standard deviation of the y-intercept and average 
slope of the calibration curve was used to calculate LOD and LOQ 
using following formulae. 
  
Where SD is the standard deviation of y-intercepts of the calibration 
curves; S is a mean slope of five calibration curves. Results for 
determination of LOD and LOQ studies are shown in table 5. 
Specificity 
The specificity of the method was determined by analyzing 
individual spot of standard drug, sample, diluent and mobile phase. 
Assay of tablets 
Twenty tablets were weighed and average weight was 
calculated. These tablets were crushed and powdered in a glass 
mortar. The tablet powder equivalent to the average weight of 
apixaban was accurately weighed, transferred to a 50 ml of 
volumetric flask and diluted up to mark with dimethyl 
formamide: methanol (1:4). The solution was filtered through 
whatman filter paper No. 41 and the first 5 ml of filtrate were 
discarded. This procedure was repeated in triplicate. The results 
of the assay of tablets are shown in table 2. 
RESULTS AND DISCUSSION 
Optimization of chromatographic conditions 
Following chromatographic conditions were chosen for analysis on 
the basis of trial and error, using different solvent systems. 
Precoated silica gel 60 f254 TLC plates were prewashed with 
methanol and activated at 110 °C for 10 min prior to application. 
The standard samples of apixaban were spotted on precoated TLC 
plates in the form of bands of length 4 mm using 100 μl sample 
syringe with a linomat-5 applicator. The chromatographic 
development was carried using toluene: methanol: diethylamine 
(16: 3: 1 v/v/v) as mobile phase with chamber saturation time of 20 
min and the migration distance of 70 mm. Densitometric scanning 
was performed using camag TLC scanners operated by win CATS 
Software (version 2.3.316286.1) and detection wavelength was 
found to be 288 nm. (fig. 2). 
Assay of marketed formulation 
The value of mean % drug was found to be 108.02 % (table 2). 
  
 
Fig. 2: Spectrum scan developed plate 
 
 
Fig. 3: UV spectrum of apixaban at 288 nm 
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Table 1: Optimized chromatographic conditions 
Parameters Details 
Mobile phase Toluene: methanol: diethylamine (16: 3: 1) v/v/v 
Plates TLC Al plates (10x10 cm) Si 60 F254 
Rf value 0.4 
Application type  Band 
Detection UV at 288 nm 
Saturation time 10 min 
Solvent front position 70.0 mm 
Application  Position Y: 8.0 mm, length: 8.0 mm,width: 0.0 mm 
Diluent Toluene: methanol: diethylamine (16: 3: 1) v/v/v 
 
Table 2: Assay of marketed formulation of apixaban 
S. No Sample solution concentration (ng/spot) Actual Concentration found (ng/spot) % Drug mean±SD* 
1 150 160.5 108.02±1.80 
2 150 162.1 
3 150 164.1 
*The value is represented as a mean±SD of 3 observations. 
 
Linearity and range 
The appropriate volume of an aliquot from standard apixaban stock 
solution was filled in the syringe under nitrogen stream by an 
automatic sample applicator. The linearity was determined by using 
working standard solutions between 50-350 ng/spot. The 
spectrums of these solutions were recorded at wavelength 288 nm. 
Calibration curve of peak area v/s concentration was plotted after 
suitable calculation and simple linear regression was performed. The 
range of solution has been decided according to statistical parameters 
of generated equation. Regression equation and correlation coefficient 
were obtained (R2 = 0.9965) shown in the fig. 4. 
 
 
Fig. 4: Calibration curve of apixaban 
 
Precision 
For repeatability studies, the spot was repeated ten times without 
changing the syringe and position of plates. Mean area, standard 
deviation, and coefficient of variance were calculated. Inter-day 
precision was determined by analyzing 200 ng/spot concentration 
of apixaban individually for ten times. The values of %RSD of 
repeatability and intermediate precision studies were found 
within the acceptable limit (table 3). Therefore, the method is 
precise.  
Accuracy  
Accuracy study was performed at a spiking level of 80, 100 and 
120% of target concentration. The values of percent recovery of the 
developed method (table 4) were found in acceptance criteria. 
Results of accuracy studies of the method were found satisfactory as 
the average mean recovery±SD was 85.66±0.79. Therefore, this 
method is accurate. 
Limit of detection (LOD) and limit of quantitation (LOQ) 
The values of LOD and LOQ have been found to be 86 ng/spot and 
262 ng/spot, respectively. 
Specificity 
Track of standard apixaban API, sample, mobile phase, and diluent 
are obtained by camag TLC scanner (fig. 5 to 8) for specificity test. 
There is no interference has been observed between the peaks of 
drug, diluent and mobile phase. Therefore, the developed method 
was found to be specific. 
 
Table 3: Repeatability and intermediate precision 
Precision Amount of drug (ng/spot) Mean area±SD* % RSD* 
Repeatability (n=10) 200 4804.4±66.89 1.389 
Inter-day (n=10) 200 4965.4±87.74 1.768 
*The value is represented as a mean±SD of 10 determinations; % RSD* relative standard deviation 
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Table 4: Accuracy study of apixaban 































 *The value is represented as a mean±SD of 3 observations. 
 
 
Fig. 5: Track of standard apixaban API 
 
 
Fig. 6: Track of apixaban sample 
 
 
Fig. 7: Track of mobile phase [toluene: methanol: diethylamine (16: 3: 1 v/v/v)] 
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Fig. 8: Track of diluent [dimethyl formamide: methanol (1:4 v/v)] 
 
CONCLUSION 
It can be concluded from the results that the proposed method is 
accurate, precise and consistent the determination of apixaban in 
tablet dosage form. This method was validated as per ICH guideline 
Q2 (R1). Results suggest that this method can be used for routine 
estimation of apixaban in bulk and pharmaceutical dosage forms.  
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